Please login to the form below

Not currently logged in
Email:
Password:

Trial success for MSD's HIV drug

MSD's Isentress has demonstrated efficacy regardless of gender or race in a diverse population of adult patients with HIV-1 infection in an observational phase III study

MSD's Isentress (raltegravir) has demonstrated efficacy and tolerability when used as part of combination therapy regardless of gender or race in a diverse population of adult patients with HIV-1 infection in an observational phase III study.

The REALMRK study enrolled a total of 209 patients, 156 of whom were black and 98 of whom were female, with data obtained compared to previous phase III studies involving Isentress.

All participants were adult HIV-1-infected patients who had not undergone treatment previously, or were failing or intolerant to current antiretroviral (ARV) treatment.

Lead investigator Dr Kathleen Squires, director of the division of infectious disease and environmental medicine, Jefferson Medical College of Thomas Jefferson University, and the study demonstrated the benefits of the drug in the diverse patient populations affected by HIV today, pointing out that black populations and women are disproportionately affected by the HIV epidemic.

MSD is known as Merck in the US and Canada.

19th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics